SBI Securities Co. Ltd. Acquires New Stake in Moderna, Inc. (NASDAQ:MRNA)

SBI Securities Co. Ltd. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 18,059 shares of the company’s stock, valued at approximately $751,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new stake in Moderna in the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after purchasing an additional 388 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MRNA. Morgan Stanley decreased their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a report on Friday, February 14th. UBS Group dropped their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Stock Performance

MRNA stock opened at $30.27 on Tuesday. The business has a 50-day simple moving average of $37.12 and a two-hundred day simple moving average of $50.28. The company has a market capitalization of $11.68 billion, a P/E ratio of -3.26 and a beta of 1.59. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.